Page last updated: 2024-12-07

4-desacetylvinblastine-3-carboxhydrazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID93303
CHEMBL ID1288707
SCHEMBL ID17529277
SCHEMBL ID19124869
MeSH IDM0155448

Synonyms (22)

Synonym
55383-37-4
vincaleukoblastin-23-oic acid, o(sup 4)-deacetyl-, hydrazide
4-desacetylvinblastine-3-carboxhydrazide
desacetylvinblastine hydrazide
4-desacetylvinblastine hydrazide
o(sup 4)-deacetyl-vincaleukoblastin-23-oic acid hydrazide
deacetylvinblastine hydrazide
desacetylvinblastine-3-carboxylic acid hydrazide
CHEMBL1288707
davlbh
f593mee9k3 ,
unii-f593mee9k3
SCHEMBL17529277
SCHEMBL19124869
DTXSID90970723
15-[5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2h-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carbohydrazonic acid
methyl (3r,5s,7r,9s)-5-ethyl-9-((3ar,3a1r,4r,5s,5ar,10br)-3a-ethyl-5-(hydrazinecarbonyl)-4,5-dihydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1h-indolizino[8,1-cd]carbazol-9-yl)-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2h-3,7-methano[1]azacyclound
o4-deacetyl-23-demethoxy-23-hydrazinylvincaleukoblastine
deacetylvinblastine hydrazide [ep impurity]
vindesine sulfate impurity c [ep impurity]
methyl (13s,15r,17s)-17-ethyl-13-[(1r,9r,10s,11r,12r,19r)-12-ethyl-10-(hydrazinecarbonyl)-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]no
AKOS040749968

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In an in vivo survival experiment, nude mice were injected with a toxic dose of DAVLBHYD and subsequently given four doses of 27."( Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody.
Corvalan, JR; Fix, DV; Gutowski, MC; Johnson, DA, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Plasma concentrations of radioactivity 1 hr after dosing were higher in monkeys than in rats."( Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys.
Althaus, WA; Kau, D; Lindstrom, TD; Ruterbories, KJ, 1990
)
0.28
" Efficacy was determined using various dosing protocols on 2-14 day established tumors of lung, pharynx, colon, and skin origin."( In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.
Briggs, SL; Hinson, NA; Laguzza, BC; Maciak, RS; Nichols, CL; Starling, JJ, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID154157In vitro inhibition of P3UCLA human adenocarcinoma cell proliferation was determined in MTT proliferation assay1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.
AID208394Concentration for 50% growth inhibition relative to untreated control in the human lung epidermoid carcinoma (T222) cell line1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Total synthesis and biological properties of novel antineoplastic (chloromethyl)furanoindolines: an asymmetric hydroboration mediated synthesis of the alkylation subunits.
AID538369Cytotoxicity against human LNCAP cells2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
AID44026In vitro inhibition of CCRF-CEM human leukemic lymphoblasts proliferation was determined1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (20.00)18.7374
1990's8 (53.33)18.2507
2000's2 (13.33)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.47 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.26%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]